Medical device manufacturer ivWatch has introduced the ivWatch Model 400 in the US.
The new ivWatch Model 400 is designed to improve patient safety through early detection of IV infiltrations and extravasations, as well as provide a new option for IV therapy.
Go deeper with GlobalData
Earlier, Peripheral IVs (PIVs) were the most commonly performed invasive medical procedure with more than 150 million IV catheters placed in the US every year.
However, current medical reports account the failure rate of IVs more than 20% due to infiltrations which will be addressed by the new ivWatch Model 400.
The PIV infiltration causes symptoms including pain and redness, as well as severe tissue damage and amputation.
In order to cater to this IV failure, clinicians have resorted to more intrusive vascular access devices like the peripherally inserted central catheters (PICC).
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataBut the device poses other serious risks, such as central-line-associated bloodstream infections, commonly referred to as CLABSIs.
The ivWatch Model 400 serves as a new option for the medical professionals to assist in a continuous monitoring of the IV allowing the peripheral IVs to be leveraged for infusion therapy resulting in reduced cost, risk, patient harm and medication dosing errors.
ivWatch CEO Gary Warren said: "It’s like a seatbelt.
"Since it’s difficult to predict when an accident will occur, people wear their seatbelt for the duration of their travel.
"Similarly, since it’s difficult to predict when an infiltration will occur, and we know it occurs too frequently, the ivWatch Model 400 represents a seat belt for patients with an IV.
"Our continuous monitoring device not only improves patient safety, but can help minimise the risk and avoidable costs for health care provider organisations."
Created over a span of 16 years of intensive development and clinical testing, the device features a non-invasive sensor that uses visible and near-infrared light to detect changes in the optical properties of the tissue.
The sensor is fitted with a highly intuitive, pole-mounted patient monitor and will notify clinicians of any potential infiltrations, enabling them to address the issue early to ensure minimum patient harm.
Last year, ivWatch Model 400 received the US food and drug administration (FDA) clearance for usage.
Image: ivWatch Model 400 to continuously monitor patient’s IV. Photo: courtesy of PR Newswire Association LLC.
